



GLYCOPROCESSING IN CLASSICAL GALACTOSAEMIA

Barry Denison Lewis MB ChB

Thesis submitted for the degree of
Doctor of Medicine
in
The University of Adelaide
(Faculty of Medicine)

April 1997

Table of Contents

TABLE OF CONTENTS	i
ABSTRACT	vii
DECLARATION	viii
ACKNOWLEDGMENTS	ix
LIST OF ABBREVIATIONS	x
<u>CHAPTER 1: GENERAL INTRODUCTION</u>	1
<u>CHAPTER 2: BACKGROUND</u>	5
2.1 INTRODUCTION	5
2.2 GALACTOSE METABOLISM	5
2.3 DISORDERS OF GALACTOSE METABOLISM	6
Galactokinase-deficiency galactosaemia (MIM 230200)	6
Epimerase-deficiency galactosaemia (MIM 230350)	7
Transferase-deficiency galactosaemia (MIM 230400)	8
Early clinical descriptions	8
Acute clinical manifestations	9
Laboratory and pathological findings	9
Diagnosis	10
Treatment	10
Treatment monitoring	11
Clinical variants	11
The 'Negro' variant	11
The Duarte variant	12
Additional variants	12
2.4 LONG-TERM COMPLICATIONS IN CLASSICAL GALACTOSAEMIA	13
A pattern emerges	13
Results of the collaborative studies	14
The five common problems	15
1. Impaired intellectual development with an apparent decline in IQ with age	15
2. Specific learning disabilities that affect speech and language development	16
3. Growth delay, more common among females than males	16
4. Disturbed coordination, gait and balance, with fine motor tremors and ataxia	16
5. Ovarian failure, represented by hypergonadotropic hypogonadism	17

	ii
Correlation between genotype and long-term outcome	18
Conclusions	19
2.5 ABNORMALITIES OF CELLULAR METABOLISM IN CLASSICAL GALACTOSAEMIA	20
Disturbed polyol metabolism	20
Galactitol	20
Myo-inositol	22
Galactonate	23
Galactose-6-phosphate	24
Galactose-1-phosphate	24
Endogenous production of galactose-1-phosphate	25
Self-intoxication with galactose-1-phosphate	25
Adverse effects of galactose-1-phosphate	26
Enzyme inhibition	26
Energy deficits	27
UDP-galactose deficiency	29
2.6 ABNORMALITIES OF GLYCOPROTEIN AND GLYCOLIPID IN CLASSICAL GALACTOSAEMIA	32
Post-mortem studies	32
Radiological studies	33
Cell culture studies	34
Abnormal serum proteins	35
Non-enzymatic galactosylation	35
Hyosialylated isoforms	36
The South Australian experience	37
2.7 CONCLUSIONS AND HYPOTHESIS	40
<u>CHAPTER 3: N-GLYCOSYLATION OF PROTEIN</u>	41
3.1 INTRODUCTION	41
3.2 THE PROCESS OF N-GLYCOSYLATION	41
Synthesis and processing of N-linked oligosaccharides	42
Synthesis and transfer of dolichol-linked oligosaccharides	42
N-linked oligosaccharide processing in the endoplasmic reticulum	45
N-linked oligosaccharide processing in the Golgi apparatus	45
3.3 THE DISORDERS OF N-GLYCOSYLATION IN HUMANS	47
Carbohydrate-deficient glycoprotein syndrome	47
Clinical features of CDG syndrome type I	48
Biochemical features of CDG syndrome type I	48

The cause of CDG syndrome	49
Disorders associated with partial defects of N-glycosylation	50
Secondary CDG syndromes in metabolic disease	50
3.4 GALACTOSAEMIC FIBROBLASTS AS A CELLULAR MODEL OF N-GLYCOSYLATION	52
Galactose oxidation	52
Galactose incorporation	52
Growth in galactose	53
Intracellular biochemistry	53
<u>CHAPTER 4: MATERIALS AND METHODS</u>	55
4.1 INTRODUCTION	55
4.2 GENERAL METHODS	55
Tissue culture	55
Cell lines	55
Media and solutions	56
Materials and reagents	57
Experimental media	57
Radiochemicals	58
Radiochemical preparation	58
Low pressure column chromatography	59
Gel filtration media	59
Columns and accessories	59
Column calibration	59
Column standardisation	60
4.3 SPECIFIC METHODS	60
Method 1: Radiolabelling, recovery, and size analysis of fibroblast N-linked oligosaccharides	60
Introduction	60
Materials and reagents	61
Method	61
A. Radiolabelling procedure	61
B. Cell harvest	62
C. Trypsin digest	62
D. PNGase F digest	62
E. Recovery of secreted glycoproteins	62
Method 2: Anion-exchange HPLC of fibroblast N-linked oligosaccharides	65
Introduction	65
Materials and Reagents	65
Method	66
A: Sample preparation	66
B: Anion-exchange HPLC programme conditions	66
C: Neuraminidase digest	66

Method 3: The specificity of the incorporation of D-[2-³H]-mannose into fibroblast N-linked oligosaccharides	69
Introduction	69
Method	69
A: Acid hydrolysis of oligosaccharides	69
B: Descending paper chromatography of monosaccharides	69
Method 4: Incorporation of D-[2-³H]-mannose into fibroblast glycoprotein relative to total protein synthesis	71
Introduction	71
Method	71
A: Radiolabelling procedure	71
B: Cell harvest and protein precipitation	71
C: Media protein precipitation	72
Method 5: Radiolabelling, recovery, and size analysis of fibroblast dolichol-linked oligosaccharides	72
Introduction	72
Reagents	73
Method	73
A: Radiolabelling procedure	73
B: Cell harvest	73
C: Extraction procedure	73
D: Clean-up procedure for the chloroform/methanol extract	74
E: Mild acid hydrolysis procedure	74
F: Recovery of protein-bound oligosaccharides	74
Method 6: Radiolabelling, immunoprecipitation, and electrophoresis of LAMP-1 from fibroblasts	76
Introduction	76
Materials and reagents	77
Method	78
A: Radiolabelling procedure	78
B: Cell harvest	78
C: Immunoprecipitation of LAMP-1	79
D: Gel preparation	79
E: Gel electrophoresis	79
F: Gel autoradiography	79

CHAPTER 5: THE STRUCTURE OF N-LINKED OLIGOSACCHARIDES FROM GALACTOSAEMIC FIBROBLASTS **80**

5.1 INTRODUCTION	80
5.2 EXPERIMENTAL PLAN	80
5.3 RESULTS OF EXPERIMENTAL PLAN A	81
5.4 RESULTS OF EXPERIMENTAL PLAN B	95
5.5 DISCUSSION	108

CHAPTER 6: GLYCOPROTEIN SYNTHESIS IN GALACTOSAEMIC FIBROBLASTS **111**

6.1 INTRODUCTION	111
6.2 EXPERIMENTAL PLAN	111
6.3 RESULTS	112
Experimental plan A	112
Experimental plan B	113
6.4 DISCUSSION	120
<u>CHAPTER 7: DOLICHOL-LINKED OLIGOSACCHARIDE SYNTHESIS IN GALACTOSAEMIC FIBROBLASTS</u>	122
7.1 INTRODUCTION	122
7.2 EXPERIMENTAL PLAN	122
7.3 RESULTS	123
7.4 DISCUSSION	136
<u>CHAPTER 8: SYNTHESIS AND PROCESSING OF A MODEL GLYCOPROTEIN IN GALACTOSAEMIC FIBROBLASTS</u>	140
8.1 INTRODUCTION	140
8.2 EXPERIMENTAL PLAN	141
8.3 RESULTS	141
Experimental plan A	141
Experimental plan B	141
8.4 DISCUSSION	144
<u>CHAPTER 9: GENERAL DISCUSSION</u>	146
SUMMARY	146
REINTERPRETATION OF THE EXPERIMENTAL EVIDENCE	147
REINTERPRETATION OF THE LONG-TERM COMPLICATIONS	149

AVENUES FOR FUTURE RESEARCH	151
APPENDICES	152
APPENDIX 1	152
Isoelectric focusing of serum transferrin isoforms	152
Introduction	152
Materials and reagents	152
Method	153
A: Sample preparation	153
B: Gel preparation	153
C: Gel electrophoresis	153
D: Immunoprecipitation and staining	153
APPENDIX 2	154
Preparation of tritiated oligosaccharide standards from RNase B and fetuin, and standardisation of the Bio-Gel P-4 sizing column	154
Introduction	154
Reagents	154
Method	154
A: Preparation of RNase B oligosaccharides	154
B: Direct reduction of RNase B-derived oligosaccharides with NaB[³ H] ₄	155
C: Mild periodate oxidation of fetuin N-linked alditols and reduction with NaB[³ H] ₄	155
BIBLIOGRAPHY	159

Abstract

Classical galactosaemia is a disorder of galactose metabolism that results from a deficiency of galactose-1-phosphate uridylyltransferase. Infants with galactosaemia usually present with an acute toxicity syndrome that is characterised by vomiting, failure to thrive, hepatitis, jaundice, and sepsis. The acute symptoms are resolved by removing galactose from the diet and this treatment has formed the basis of management of galactosaemia for over 60 years. However, as a group, the galactosaemic patients develop longer term problems that include impaired intellectual development, learning disabilities, poor motor function, ovarian failure, and occasionally ataxia and tremor. These long-term complications develop independent of either the severity of initial illness, the age at which diet was started, or the success of dietary control.

If the long-term complications are not related to the acute toxicity of galactosaemia, then other explanations must be sought in alterations of the cellular environment that occur secondary to transferase deficiency. The serum in untreated galactosaemia contains hyposialylated isoforms of several glycoproteins. This suggests a possible disturbance in glycoprotein synthesis, which could contribute to the long-term complications. The aim of this thesis was to examine N-glycosylation in transferase-deficient skin fibroblasts to determine what abnormalities of glycoprotein synthesis occur in galactosaemia. When the mature complex N-linked oligosaccharides from galactosaemic fibroblasts were examined by size-exclusion chromatography and anion-exchange high performance liquid chromatography, they were structurally complete. However, the galactosaemic fibroblasts consistently incorporated less [2-³H]-mannose into protein than normal controls. This occurred whether the incorporation was corrected to the cell protein or to the incorporation of [³⁵S]-methionine. The decrease was observed in cellular and secreted proteins and was proportional to the concentration of galactose in the culture medium. The galactosaemic fibroblasts also incorporated less [2-³H]-mannose into dolichol-linked oligosaccharides. This was accompanied by an accumulation of Man₃-₅GlcNAc₂ dolichol-linked intermediates, and predominantly Man₅GlcNAc₂-sized oligosaccharides were transferred to protein. These abnormalities are very similar to those reported in fibroblasts from patients with the carbohydrate-deficient glycoprotein syndrome type I, and in cells starved of glucose.

It is proposed that galactose-1-phosphate interferes with the conversion of glucose to mannose intermediates that are required for the synthesis of dolichol-linked oligosaccharides. This may be one mechanism for hyposialylation of serum glycoproteins in untreated galactosaemia. It remains to be determined whether abnormal N-glycosylation contributes to the long-term complications in patients.